Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 10Active not recruiting 3Unknown 2Terminated 2Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Breast Neoplasms 24Carcinoma, Non-Small-Cell Lung 20Colorectal Neoplasms 19Neoplasms 18Recurrence 17Pancreatic Neoplasms 17Multiple Myeloma 15Prostatic Neoplasms 12Advanced Solid Tumors 12Advanced Solid Tumor 12Carcinoma, Hepatocellular 11Stomach Neoplasms 10Ovarian Neoplasms 10Leukemia, Myeloid, Acute 10Triple Negative Breast Neoplasms 8Small Cell Lung Carcinoma 7Neoplasm Metastasis 7Melanoma 7Squamous Cell Carcinoma of Head and Neck 6Lymphoma, Large B-Cell, Diffuse 6Head and Neck Neoplasms 6Glioblastoma 6Urinary Bladder Neoplasms 5Solid Tumors 5Solid Tumor 5Lymphoma, B-Cell 5Lung Neoplasms 5Liver Neoplasms 5Glioma 5Endometrial Neoplasms 5

Interventions

RC48 antibody 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Not yet recruiting × Salivary Gland Neoplasms × Clear all
NCT05898373 2023-06-12

Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC

Peking Union Medical College

Phase 1/2 Not yet recruiting
120 enrolled
Head & Neck

Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡